KALTF - Kalytera Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0340
+0.0046 (+15.65%)
At close: 3:30PM EDT
Stock chart is not supported by your current browser
Previous Close0.0294
Open0.0350
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0307 - 0.0350
52 Week Range0.0248 - 0.1382
Volume146,534
Avg. Volume257,076
Market Cap15.482M
Beta (3Y Monthly)-0.59
PE Ratio (TTM)N/A
EPS (TTM)-0.0250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Kalytera Announces Completion of Food Effect and QTc Study

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has completed Study KAL-07, the Food Effect and QTc Study, that is part of the Company’s product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). Preliminary results for the Food Effect and QTc Study are positive and as expected.

  • GlobeNewswire17 days ago

    Kalytera to Hold Annual and Special Meeting on July 29, 2019

    SAN FRANCISCO and TEL AVIV, Israel, July 05, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that it is.

  • GlobeNewswire25 days ago

    Kalytera to Acquire CBD Extraction Business

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that it has signed a Letter of Intent (“LOI”) to acquire a majority interest in Oregon 01, LLC (doing business as “Clean Bi Design”), which will operate a hemp-based cannabidiol (“CBD”) extraction facility in Amity, Oregon. Under the LOI, Kalytera has agreed to invest USD $3.5 million for the acquisition of a 51% interest in the business. The extraction facility will be both GMP certified and FDA compliant, and equipped with state-of-the-art equipment for extraction, distillation and isolation.

  • GlobeNewswire27 days ago

    Kalytera Provides Update on GVHD Program

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided an update on its lead product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). To date, the results of Kalytera’s Phase 2 clinical study have been positive and encouraging. No patients in the first (low dose) cohort developed grades 3 or 4 acute GVHD while receiving oral CBD treatment, and only one patient developed grade 2 acute GVHD.

  • GlobeNewswirelast month

    Kalytera Announces Grant of Stock Options to Directors

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has granted stock options on June 19, 2019 to the directors of the Company.  The stock options have an exercise price of $0.05 per common share and expire ten years from the date of grant.  One third of the options granted will vest on June 19, 2020 and the remaining options will vest in twenty-four (24) equal monthly installments commencing July 2020. Stock options to purchase 68,698 common shares of Kalytera were granted to Ron Erickson, stock options to purchase 254,345 common shares were granted to Jeff Paley, and stock options to purchase 1,000,000 common shares were granted to Rob Hutchison, who very recently joined the Company’s board of directors.

  • GlobeNewswirelast month

    Kalytera Announces Changes to Board of Directors

    Mr. Robin “Rob” Hutchison has joined the Board to fill the vacancy created by the resignation of Mr. Gary Leong, an independent director who also served on the Company’s Audit and Governance and Nominating Committees. Mr. Hutchison, who is an independent director, will also serve as a member of the Company’s Audit, Compensation and Governance and Nominating Committees.

  • GlobeNewswirelast month

    Kalytera Announces Additional Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has invented a novel first-in-class cannabinoid molecule, designated KAL-1816, that strongly and selectively binds with and activates the alpha3 glycine pain receptor. Activation of the alpha3 glycine receptor shuts down pain transmission in inflammatory conditions, such as arthritis, colitis, and sciatica. “Today’s announcement is a milestone in Kalytera’s search for a breakthrough cannabinoid analgesic that will operate via a wholly new pathway,” stated Robert Farrell, Kalytera’s President and CEO.

  • GlobeNewswire2 months ago

    Kalytera Reports First Quarter 2019 Financial Results

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the first quarter of 2019. “Since the beginning of the year, we have made important progress in our lead product development program," stated Robert Farrell, Kalytera’s President and CEO. In the first quarter (“Q1”) of 2019, the Company recorded a net loss of approximately $6.4 million ($0.021 per Common Share), compared with a net loss of approximately $1.9 million ($0.01 per Common Share) in Q1 2018.

  • GlobeNewswire2 months ago

    Kalytera Announces Submission of Patent Application to the U.S. Patent and Trademark Office

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (“USPTO”) covering Kalytera’s novel compositions of cannabidiol (“CBD”) in combination with certain metabolites of the human microbiome as a potential treatment for ulcerative colitis, Crohn’s disease, inflammatory bowel disease (“IBD”), graft versus host disease (“GVHD”) and other GI tract inflammatory diseases.

  • GlobeNewswire2 months ago

    Kalytera Announces Data Further Elucidating CBD’s Mechanisms of Action in Prevention of GVHD

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced new laboratory findings demonstrating that cannabidiol (“CBD”) acts through a distinct biological pathway to restore epithelial cell tight junction integrity, which is highly important in preventing acute graft versus host disease (“GVHD”) and associated comorbidities. Acute GVHD is a life-threatening complication commonly occurring after bone marrow transplant procedures. Prior to the bone marrow transplant, patients typically undergo a total body irradiation (“TBI”) procedure.

  • GlobeNewswire2 months ago

    Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has engaged Echelon Wealth Partners to determine the value, on a risk-adjusted basis, of its cannabidiol ("CBD") therapeutic products for the prevention and treatment of graft versus host disease ("GVHD"), and to assist with the review of potential out-licensing opportunities for the commercial rights to these products. Kalytera has recently received unsolicited inquiries from companies interested in the rights to Kalytera’s GVHD products, and, in response to these inquiries, Kalytera’s board of directors approved the engagement of Echelon.

  • GlobeNewswire2 months ago

    Kalytera Therapeutics, Inc. Announces Second Closing of Public Offering

    Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. SAN FRANCISCO and TEL AVIV, Israel, May 14, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX Venture: KLY) (KALTF) (the “Company” or “Kalytera”) is pleased to announce the second closing of its previously announced public offering (the “Offering”) of units of the Company (“Units”) for aggregate gross proceeds of CDN$1,617,500.

  • GlobeNewswire3 months ago

    Kalytera Reports 2018 Financial Results

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the year ended December 31 2018. Investors should note that the Company’s TSXV ticker symbol was recently changed from "KALY" to "KLY". For 2018, the Company recorded net income of approximately $6.9 million ($0.04 per Common Share), compared with a net loss of approximately $31.9 million ($0.26 per Common Share) in 2017.

  • GlobeNewswire3 months ago

    Kalytera Therapeutics, Inc. Announces Closing of Public Offering

    Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. SAN FRANSISCO and TEL AVIV, Israel, April 26, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX Venture: KLY) (KALTF) (the “Company” or “Kalytera”) is pleased to announce the closing of its previously announced public offering (the “Offering”) of units of the Company (“Units”) for aggregate gross proceeds of CDN$6,758,300.  Echelon Wealth Partners Inc. (“Echelon”) and Paradigm Capital Inc. (and together with Echelon, the “Agents”) acted as agents for and on behalf of the Company in connection with the Offering.

  • GlobeNewswire3 months ago

    Kalytera Therapeutics Announces Filing of Short Form Prospectus

    Kalytera Therapeutics, Inc. (the “Company”, or “Kalytera”) (KALY.V) (KALTF) announced today that it has filed a final short form prospectus (the “Final Prospectus”) with securities regulatory authorities in the provinces of Alberta, British Columbia and Ontario (and received a receipt therefor) in connection with its previously announced marketed offering of a minimum of 90,000,000 units of the Company (“Units”, or each a “Unit”) and a maximum of 200,000,000 Units for gross proceeds of $4,500,000 to $10,000,000 (the “Offering”). The first closing of the Offering is expected to occur on or about April 26, 2019, or such other date or dates as the Company and the Agents (as defined below) may agree (the “Closing Date”).

  • GlobeNewswire4 months ago

    Kalytera Therapeutics Announces Short Form Prospectus Offering of Units

    Kalytera Therapeutics, Inc. (the “Company”, or “Kalytera”) (TSXV:KALY and OTCQB: KALTF) announced that it has filed a preliminary short form prospectus with the securities regulatory authorities in the provinces of Alberta, British Columbia and Ontario in connection with a proposed marketed offering of units of the Company (“Units”, or each a “Unit”) for gross proceeds of $4,500,000 to $10,000,000 (the “Offering”). Echelon Wealth Partners Inc. (the “Lead Agent”) and Paradigm Capital Inc. (collectively with the Lead Agent, the “Agents”) will conduct the Offering on a commercially reasonable efforts basis as the Company’s agents for the Offering in Canada.  The Units may also be offered for sale in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and applicable state laws.

  • GlobeNewswire4 months ago

    Kalytera Reports Data for First Cohort in Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced positive data from its ongoing Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) following bone marrow transplant.

  • GlobeNewswire5 months ago

    Kalytera Announces Closing of Private Placement of Convertible Debenture Units

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") is pleased to announce the closing of its previously announced non-brokered private placement (the “Offering”) under which it sold C$787,500 aggregate principal amount of convertible debenture units for an aggregate purchase price of C$750,000 (representing an original issue discount equal to 5% of the purchase price).  The convertible debenture units consist of an aggregate of $787,000 principal amount of 10.0% secured convertible debentures (the “Convertible Debentures”) and an aggregate of 12,115,384 common share purchase warrants (each, a “Warrant”). The Convertible Debentures will bear interest from the date of closing at 10.0% per annum, payable quarterly in arrears on the last business day of May, August, November and February of each year commencing May 31, 2019, and will mature on March 6, 2021 (the “Maturity Date”).  The Company’s obligations under the Convertible Debentures will be guaranteed by its material subsidiaries, and such guarantee obligations will be secured by substantially all of the assets of such subsidiaries.

  • GlobeNewswire5 months ago

    Kalytera Announces Initiation of Study KAL-07 – Food Effect Study

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has initiated a food effect study (“Study KAL-07”), as part of its lead product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). Study KAL-07 is being initiated pursuant to written guidance received from U.S. Food and Drug Administration (the “FDA”).  The FDA is requiring that the Company complete a study in healthy volunteers to assess the effect of food intake on the absorption of oral CBD, prior to initiation of a Phase 3 registration study.

  • GlobeNewswire5 months ago

    Kalytera Announces Private Placement of Convertible Debenture Units

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") announced today that it is proceeding with a private placement (the “Offering”) under which it intends to sell C$787,500 aggregate principal amount of convertible debenture units for an aggregate purchase price of C$750,000 (representing an original issue discount equal to 5% of the purchase price).  The convertible debenture units will consist of an aggregate of $787,000 principal amount of 10.0% secured convertible debentures (the “Convertible Debentures”) and an aggregate of 12,115,384 common share purchase warrants (each, a “Warrant”). The Convertible Debentures will bear interest from the date of closing at 10.0% per annum, payable quarterly in arrears on the last business day of May, August, November and February of each year commencing May 31, 2019, and will mature two years following the closing of the Offering (the “Maturity Date”).

  • GlobeNewswire5 months ago

    Kalytera Announces Share Issuance for January Invoices under Payments Agreements with Salzman Group

    SAN FRANCISCO and TEL AVIV, Israel, Feb. 26, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the.

  • GlobeNewswire5 months ago

    Kalytera Completes Deferral Transaction with Former Shareholders of Talent Biotechs

    SAN FRANCISCO, and TEL AVIV, Israel, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today completed certain transactions contemplated by the arrangements reached with the former shareholders of Talent Biotechs Ltd. of Israel (“Talent”) on terms that were previously announced in August 2018. As previously announced in August 2018, the current balance owing to the former Talent shareholders under these milestone payments is US$1,988,620 plus interest, which debt is evidenced by a promissory note maturing July 31, 2019 bearing interest at the rate of 8% per annum.  This promissory note has been issued by a subsidiary of the Company and is secured by the rights of Talent as licensee under the Exclusive License Agreement with MOR.

  • GlobeNewswire5 months ago

    Kalytera Reports Additional Positive Data for CBD in Prevention of Acute GVHD

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced additional positive interim data from its ongoing Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) following bone marrow transplant. Kalytera previously announced, on December 20, 2018, that no patients in the Phase 2 clinical study had developed grades 3 or 4 acute GVHD while receiving oral CBD treatment, and that only one patient had developed grade 2 acute GVHD.

  • GlobeNewswire6 months ago

    Kalytera Announces Change to Scope of Services under Payments Agreements with Salzman Group and Next Share Issuance

    Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 13,085,677 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under the payments agreement announced on June 15, 2018 (the “June 2018 Agreement”).  Under the June 2018 Agreement, The Salzman Group and its affiliates provide general and administrative support services, study set-up work for planned studies in connection with use of CBD in treatment of GVHD, and research and development work in connection with Kalytera’s exclusive license of cannabidiol-naproxen conjugates for treatment of pain.

  • GlobeNewswire6 months ago

    Kalytera Announces Grant of Stock Options to Certain Directors and Employees

    SAN FRANCISCO and TEL AVIV, ISRAEL , Jan. 28, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has granted stock options on January 25, 2019 to certain directors and employees of the Company.  The stock options have an exercise price of $0.085 per common share and expire ten years from the date of grant.  One third of the options granted will vest on January 25, 2020 and the remaining options will vest in twenty-four (24) equal monthly installments commencing February 2020. Stock options to purchase 1,129,318 common shares of Kalytera were issued to each of Ron Erickson and Jeff Paley, who are independent members of the Company’s board of directors, and stock options to purchase 1,246,092 common shares of Kalytera were issued to Robert Farrell, a director and the Chief Executive Officer of the Company.  Stock options to purchase 300,000 common shares of Kalytera were issued to Victoria Rudman, the Company’s Interim Chief Financial Officer, while Drs. Prutchi-Sagiv and Yeshurun were each granted stock options to purchase 600,000 common shares of the Company.